Catalyst Edge · Scanner · Tickers · EXEL
CATALYST DOSSIER · UPDATED 2026-09-18

$EXEL

biotech · convergence 20 · conviction ELEVATED
Convergence Score
20
Conviction
ELEVATED
Signals Firing
9
Track Record
3/3
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $EXEL?

EXEL 20 ELEVATED biotech

Quantitative

  • Net Income (CY2026Q2): $212.1M (+14.7% YoY)

Catalysts

  • Clinical trial milestone: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Risks

  • Position-sizing discipline: Conviction ELEVATED (20 score) — size accordingly; no specific catalyst-fade risk flagged

Bear case

  • Squeeze unwind: Short interest can compress before retail catches the move — entry timing critical

Sympathy basket (cerebro)

  • REZI via consumer r=+0.96 sympathetic (score 53)
  • RENT via consumer r=+0.96 sympathetic (score 45)
  • NFE via utilities r=+0.71 sympathetic (score 61)
  • OPTT via utilities r=+0.71 sympathetic (score 36)
  • HAIN via staples r=+0.64 sympathetic (score 26)
  • RAKR via staples r=+0.64 sympathetic (score 23)

Signals Firing

finra_shortclinicalsec_fdaauto_setup_classifierauto_macro_13f_whalesauto_macro_eia_petroleumauto_macro_sec_proxy_fightauto_macro_term_premiumauto_macro_wiki_pageviews
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Pick Track Record

DateListNext-day max runNext-day closeHit +2%?
2026-08-31sec_clean_gappers+4.3%+4.1%✓ hit
2026-08-31sec_top_gappers+4.3%+4.1%✓ hit
2026-08-31sec_top_moat_emerging+4.3%+4.1%✓ hit
Lifetime: 3/3 wins · hit-rate 100.0% on +2% intraday

Sympathy Basket

Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.

You came here for EXEL. You found it after it moved, the same way everyone else did.

$99 once — every ticker on this site ranked before the open.

Tier 1 setups touched +2% intraday 48.9% of the time across 374 tracked calls. Baseline for everything else: 40.9%. That is a +8.0 point edge, measured from the NEXT OPEN — the first price you could actually pay, not the prior close. We publish the misses too: https://catalystedgescanner.com/trust/

  1. Click Become a Founding Member below.
  2. Pay $99 once — not monthly, not ever again.
  3. You keep every future release at that price. Tomorrow's ranked list lands at 3:30 AM ET, before the open.

29 of 30 founding seats left. The price goes up when they are gone.

Become a Founding Member — $99 once

One payment. Lifetime access. The free daily picks stay free — this is for people who want the full console. Not buying today? Get tomorrow's ranked list free →